Androgen deprivation therapy for prostate cancer: Current status and future prospects

Prostate

Volumn 61, Issue 4, 2004, Pages 332-353

  Miyamoto, Hiroshi ^a   Messing, Edward M ^a   Chang, Chawnshang ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Androgen receptor; Androgen receptor coregulator; Androgen independent prostate cancer; Antiandrogen; Antiandrogen withdrawal syndrome

Indexed keywords

ABARELIX; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BENZOQUINOLINE; BICALUTAMIDE; CARBOPLATIN; CORTICOSTEROID; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTRAMUSTINE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; LY 320236; MEGESTROL ACETATE; MITOXANTRONE; NILUTAMIDE; PACLITAXEL; PREDNISONE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINBLASTINE;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALCOHOL INTOLERANCE; AR GENE; ARA55 GENE; ARA70 GENE; ARTICLE; BRACHYTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; DRUG MECHANISM; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENE; GYNECOMASTIA; HISTAMINE RELEASE; HORMONE DEPENDENCE; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER TOXICITY; MALE; MOLECULAR MECHANICS; MONOTHERAPY; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RESPIRATORY FAILURE; SIDE EFFECT; SURVIVAL RATE; VISUAL DISORDER;

ANDROGEN ANTAGONISTS; ANDROGENS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIETHYLSTILBESTROL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RECEPTORS, ANDROGEN; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT FAILURE;

EID: 9644279380     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20115     Document Type: Article

References (220)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2. Jemal A, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988;240:324-326.
4. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee H-J, Wang C, Mizokami A. Androgen receptor: An overview. Crit Rev Eukaryot Gene Expr 1995;5:97-125.
5. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895.
6. Tsai M-J, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-486.
7. Beato M, Herrlich P, Schütz G. Steroid hormone receptors: Many actors in search of a plot. Cell 1995;83:851-857.
8. Chang C, Kokontis J. Identification of a new member of the steroid receptor super-family by cloning and sequence analysis. Biochem Biophys Res Commun 1988;155:971-977.
9. Enmark E, Gustafsson J-Å. Orphan nuclear receptors - The first eight years. Mol Endocrinol 1996;10:1293-1307.
10. Lee Y-F, Lee H-J, Chang C. Recent advances of the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. J Steroid Biochem Mol Biol 2002;81:291-308.
11. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989; 59:477-487.
12. Daniellian PS, White R, Lees JA, Parker MG. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 1992;11:1025-1033.
13. Jenster G, van der Korput HAGM, Trapman J, Brinkmann AO. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995;270:7341-7346.
14. 2-terminal domain. J Biol Chem 1999;274:37219-37225.
15. Jenster G. Coactivators and corepressors as mediators of nuclear receptor function: An update. Mol Cell Endocrinol 1998;143:1-7.
16. Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998;10:373-383.
17. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20:321-344.
18. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: An overview. Endocr Rev 2002;23:175-200.
19. Russell DW, Wilson JD. Steroid 5α-reductase: Two genes/two enzymes. Annu Rev Biochem 1994;63:25-61.
20. Geller J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol 1985;12(Suppl 1):28-35.
21. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-1550.
22. 5- androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95:11083-11088.
23. Miyamoto H, Chang C. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 2000;7:32-34.
24. Navarro D, Luzardo OP, Fernändez L, Chesa N, Díaz-Chico BN. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 2002;81:191-201.
25. Langley E, Zhou Z, Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 1995;270:29983-29990.
26. Ikonen T, Palvimo JJ, Jänne OA. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 1997;272:29821-29828.
27. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000;27:39-66.
28. Hsing AW. Hormones and prostate cancer: What's next? Epidemiol Rev 2001;23:42-58.
29. Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor - An update of mechanisms of action in prostate cancer. Urol Res 2000;28:211-219.
30. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1994;5:545-557.
31. Jin B, Turner L, Walters WAW, Handelsman DJ. Androgen or estrogen effects on human prostate. J Clin Endocrinol Metab 1996;81:4290-4295.
32. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15: 233-250.
33. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991;129:3187-3199.
34. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: Cell death mediated by vascular regression. Curr Opin Urol 2000;10:415-420.
35. Katz AE, Benson MC, Wise GJ, Olsson CA, Bandyk MG, Sawczuk IS, Tomashefsky P, Buttyan R. Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 1989;49:5889-5894.
36. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-723.
37. Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133:620-621.
38. The Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: Treatment comparisons. J Urol 1967;98:516-522.
39. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
40. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-1130.
41. Chad wick DJ, Gillatt DA, Gingell JC. Medical or surgical orchiectomy: The patients' choice. BMJ 1991;302:572.
42. Fosså SD, Aass N, Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol 1994;21:657-661.
43. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: Regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19:72-80.
44. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311:1281-1286.
45. deVoogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S, and members of the European Organization for Research on Treatment of Cancer Urological Group. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostate cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 1986;135:303-307.
46. Emtage LA, Trethowan C, Kelly K, Arkell D, Wallace DM, Hughes M, Hay A, Blacklock R, Jones M, Rouse A, Farrar D, Young C, Blackledge G. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: A West Midlands Urological Research Group Study. Prog Clin Biol Res 1989;303:47-52.
47. Citrin DL, Resnick MI, Guiman P, Al-Bussam N, Scott M, Gau TL, Kennealey GT. A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of randomized, multicenter trial. Prostate 1991;18:139-146.
48. Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, White R, Schinella R, Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. J Clin Oncol 1996;14:2250-2257.
49. Byar DP, Corle DK. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. J Natl Cancer Inst Monogr (NCI Monogr) 1988;7:165-170.
50. Robinson MR, Smith P, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC genito-urinary tract cancer co-operative group phase III clinical trial (protocol 30805) comparing orchiectomy, orchiectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995;28:273-283.
51. Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: A personal view. Br J Urol 1996;78:921-928.
52. Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer. Ann Oncol 2000;11:177-181.
53. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(Suppl 2A):108-113.
54. Kitahara S, Yoshida K, Ishizaka K, Kageyama Y, Kawakami S, Tsuji T, Oshima H. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J 1997;44:527-532.
55. Kitahara S, Umeda H, Yano M, Koga F, Sumi S, Moriguchi H, Hosoya Y, Honda M, Yoshida K. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 1999,46:659-664.
56. Mangan FR, Neal GE, Williams DC. The effects of diethyl-stilboestrol and castration on the nucleic acid and protein metabolism of rat prostate gland. Biochem J 1967;104:1075-1081.
57. 75seleno-methionine by prostatic carcinoma cells. Br J Urol 1988;62:166-172.
58. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim L-S, Fine RC. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88:908-917.
59. Castle EP, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Urol Clin North Am 2002;29:71-81.
60. Lau K-M, LaSpina M, Long J, Ho S-M. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-3182.
61. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61:1919-1926.
62. Signoretti S, Loda M. Estrogen receptor β in prostate cancer: Brake pedal or accelerator? Am J Pathol 2001;159:13-16.
63. Yeh S, Miyamoto H, Shima H, Chang C. From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 1998;95:5527-5532.
64. Labrie F, Belanger A, Susan L, Labrie C, Simard J, LuuThe V, Diamond P, Gomez J-L, Candas B. History of LHRH agonist and combination therapy in prostate cancer. Endocr Relat Cancer 1996;3:243-278.
65. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54:4091-4095.
66. Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999;38: 151-158.
67. Denis L. European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996. Urology 1998;51(Suppl 5A):50-57.
68. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 2000;132:566-577.
69. Tunn UW, Bargelloni U, Cosciani S, fiaccavento G, Guazzieri S, Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advance prostate cancer. Urol Int 1998; 60(Suppl 1):9-16.
70. Stege R. Potential side effects of endocrine treatment of long duration in prostate cancer. Prostate 2000;(Suppl 10):38-42.
71. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(Suppl 2A):5-9.
72. Labrie F, Dupont A, Belanger A, Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 1987;138:804-806.
73. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: New approaches to treatment. Oncologist 2000;5:162-168.
74. Stricker HJ. Luteinizing hormone-releasing hormone antagonists in prostate cancer. Urology 2001;58(Suppl 2A): 24-27.
75. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB, for the Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;8:756-761.
76. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB, for the Abarelix Study Group. The Gonadotropin- releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-1589.
77. Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Fotheringham N, Campion M, Garnick MB, and Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167: 1670-1674.
78. Labrie F, Dupont A, Giguere M, Borsanyi J-P, Lacouraere Y, Montette G, Emond J, Bergeron N. Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 1988;61:341-346.
79. Sandow J, von Rechenberg W, Engelbart K. Pharmacological studies on androgen suppression in therapy of prostate carcinoma. Am J Clin Oncol 1988;11(Suppl 1):S6-S10.
80. Muggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer: Clinical features and urinary excretion of 17-ketosteroids and estrogen. Ann Surg 1945;122:1031-1041.
81. Boccardo F. Hormone therapy of prostate cancer: Is there a role for antiandrogen monotherapy? Crit Rev Oncol Hematol 2000;35:121-132.
82. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355:1491-1498.
83. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr A, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
84. Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F, Martorana G, Giuliani L, Selvaggi F, Battaglia M, Ponti UD, Petracco S, Cortellini P, Ziveri M, Ferraris U, Bruttini GP, Epis R, Comeri G, Gallo G, and other participants in the Italian Prostatic Cancer Project (PONCAP) Study Group. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993;29:1088-1093.
85. Denis LJ, Whelan P, de Moura JCL, Newling D, Bono A, De Pauw M, Sylvester R. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 1993;42:119-132.
86. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Suva FC, Chisholm G, Crawford ED, Debruyne FMJ, Dijkman GD, Frick J, Goedhals L, Knönagel H, Venner PM. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149: 77-83.
87. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-1042.
88. Schmitt B, Wilt TJ, Schellhammer PF, De Masi V, Sartor O, Crawford ED, Bennett CL. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review. Urology 2001;57:727-732.
89. Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Mattelaer J, D'Hulster D, Mahler C. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol 1994;41: 525-530.
90. Goldenberg SL, Bruchovsky N. Use of cyproterone acetate in prostate cancer. Urol Clin North Am 1991;18:111-122.
91. de Voogt HJ. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate 1992;(Suppl 4):91-95.
92. Iversen P. Antiandrogen monotherapy: Indications and results. Urology 2002;60(Suppl 3A):64-71.
93. Delaere KPJ, Van Thillo EL. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 1991; 18(Suppl 6):13-18.
94. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996;155:209-212.
95. McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997;2: 18-27.
96. McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer: A review of treatment options. Urology 2000;56:713-720.
97. Kolvenbag GJCM, Iversen P, Newling DWW. Antiandrogen monotherapy: A new form of treatment for patients with prostate cancer. Urology 2001;58(Suppl 2A):16-23.
98. Decensi AU, Boccardo F, Guarneri D, Positano N, Parletti MC, Costantini M, Martorano G, Giuliani L, for the Italian Prostatic Cancer Project. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991;146:377-381.
99. Dole EJ, Holdsworth MT. Nilutamide: An antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997;31:65-75.
100. Kolvenbag GJCM, Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 1999;39:47-53.
101. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996;47(Suppl 1A):38-43.
102. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomized comparison of 'Casodex'™ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-456.
103. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TLJ, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-1582.
104. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: A preliminary report. Eur Urol 1994;26(Suppl):10-14.
105. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Crucinni G, Dannino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montetiore F, Portoghese F, Spano G, for the Italian Prostate Cancer Project. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study. J Clin Oncol 1999;17:2027-2038.
106. Katchen B, Buxbaum S. Disposition of a new, nonsteroidal, antiandrogen, α,α,α-trifluoro-2-methy-4′-nitro-m-propionotoluidide (flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 1975;41:373-379.
107. McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, Yates RA. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993;23:1241-1253.
108. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DMA, Delaere KPJ, Vaage S, Tammela TLJ, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJCM. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 2002;168:429-435.
109. Langeler EG, Connie JC, van Uffelen CJC, Blankenstein MA, van Steenbrugge GJ, Mulder E. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 1993;23:213-223.
110. Akakura K, Bruchovsky N, Goldernberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-2790.
111. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 1996;58:139-146.
112. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58:2546-2550.
113. Higano CS, Elite W, Russel K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 1996;48:800-804.
114. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 1999;53:530-534.
115. Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwano S, Baba S. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Jpn J Clin Oncol 2000;30:21-26.
116. Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Intermittent androgen suppression in prostate cancer: The Canadian experience. Urology 2002;60(Suppl 3A):52-56.
117. Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Prospective determination of the hormonal response after cessation of lutenizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999;53:898-903.
118. Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 2003;169:251-255.
119. Leibowitz RL, Tucker SJ. Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients. Oncologist 2001;6:177-182.
120. Labrie F, Cusan L, Gomez J-L, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Candas B. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994;44(Suppl 6A):29-37.
121. Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model. J Urol 1997;157:1727-1730.
122. Aus G, Abrahamsson P-A, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K. Three-month neoadjuvant hormonal therapy before radical prostatectomy. A 7-year follow-up of a randomized controlled trial. BJU Int 2002;90: 561-566.
123. Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: A detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002;26:1400-1413.
124. Hurtado-Coll A, Goldenberg SL, Klotz L, Cleave ME. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: The Canadian experience. Urology 2002; 60(Suppl 3A):45-51.
125. 0 prostate cancer: 5-year results. J Urol 2002;167:112-116.
126. Gleave ME, Goldenberg L, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, and the Canadian Uro-oncology Group. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 2001;166:500-507.
127. Zincke H, Lau W, Bergstralh E, Blute ML. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001;166:2208-2215.
128. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-1788.
129. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: Results at 10 years of EST 3886 [Abstract]. J Urol 2003;169(Suppl 4):396.
130. Wirth M, Frohmüller H, Marx F, Bolten M, Theiß M. Randomized multicenter trials on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery-Interim analysis of treatment effect and prognostic factors [Abstract]. Br J Urol 1997;80:263.
131. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849-854.
132. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Updated results of the phase III Radiation Therapy Oncology Group (ROTG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-946.
133. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (ROTG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-1252.
134. D'Amico AV. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 2002;60(Suppl 3A):32-38.
135. Pollack A, Kuban DA, Zagars GK. Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 2002;60(Suppl 3A):22-31.
136. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier I, Kuten A, Sternberg C, Mattelaer J, Torecilla JL, Pfeffer JR. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002;360:103-108.
137. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:947-956.
138. Lee WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 2002;60(Suppl 3A):39-44.
139. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-841.
140. Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology 2002;60(Suppl 3A):94-100.
141. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79:196-202.
142. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 1999;18:1050-1057.
143. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990;17:175-187.
144. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339-343.
145. Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: Preliminary results. Semin Oncol 2001;28(Suppl 15):22-31.
146. Kaplan SA. 5α-reductase inhibitors: What role should they play? Urology 2001;58(Suppl 6A):65-70.
147. Ornstein DK, Smith DS, Andriole GL. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 1998;52:1094-1097.
148. Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J, Schröder F. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. Prostate 1999;40:105-114.
149. McNulty AM, Audia JE, Bemis KG, Goode RL, Rocco VP, Neubauer BL. Kinetic analysis of LY320236: Competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase. J Steroid Biochem Mol Biol 2000;72:13-21.
150. Ruizeveld de Winter JA, Janssen PJA, Sleddens HMEB, Verleun-Mooijman MCT, Trapman J, Brinkmann AO, Santerse AB, Schröder FH, van der Kwast TH. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994;144:735-746.
151. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TLJ, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-3555.
152. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001;1: 34-45.
153. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60(Suppl 3A):132-139.
154. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi O-P. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319.
155. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The androgen receptor gene mutations database. Nucleic Acids Res 1998;26:234-238.
156. Taplin M-E, Bubley GJ, Ko Y-J, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-2515.
157. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285.
158. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastman J, Weigel NL, Lamb DJ. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-949.
159. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E. A Mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540.
160. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic
161. Yeh S, Kang H-Y, Miyamoto H, Nishimura K, Chang H-C, Ting H-J, Rahman M, Lin H-K, Fujimoto N, Hu Y-C, Mizokami A, Huang K-E, Chang C. Differential induction of androgen receptor transactivation by different androgen receptor coactivatos in human prostate cancer DU145 cells. Endocrine 1999;11: 195-202.
162. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001;58:289-294.
163. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-4319.
164. Labrie F, Cnadas B. Androgen blockade in prostate cancer. Lancet 2000;356:341-342.
165. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999;69: 307-313.
166. Wang LG, Liu XM, Kreis W, Budman DR. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun 1999;259:21-28.
167. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-1697.
168. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
169. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999;19:5143-5154.
170. Wen Y, Hu MC-T, Makino K, Spohn B, Bartholomeusz G, Yan D-H, Hung M-C. Her-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-6845.
171. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Jänne OA. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 1994;135:1359-1366.
172. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-19907.
173. Lin D-L, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through upregulation of androgen receptor expression. Clin Cancer Res 2001;7:1773-1781.
174. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-187.
175. Drachenberg DE, Elgamal AA-A, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-133.
176. Shi Y, Brands FH, Chatterjee S, Feng A-C, Groshen S, Sehewe J, Lieskovsky G, Cote RJ. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166:1514-1519.
177. Berger SL. Gene activation by histone and factor acetyltransferases. Curr Opin Cell Biol 1999;11:336-341.
178. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati M-L, Pestell RG. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 2000;275:20853-20860.
179. Raffo AJ, Perlman H, Chen M-W, Day ML, Stretman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistence to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
180. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
181. Miyoshi Y, Uemura H, Fujinami K, Mikata M, Harada M, Kitamura K, Koizumi Y, Kubota Y. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000;43:225-232.
182. Abrahamsson P-A. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-148.
183. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-273.
184. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265.
185. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149:607-609.
186. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndrome. Urol Clin North Am 1997;24:421-431.
187. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995;76:1428-1434.
188. Furuya Y, Akimoto S, Akakura K, Igarashi T, Murakami S, Shimazaki J, Ito H. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 1998;60:28-32.
189. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989;14:103-115.
190. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 1996;29:153-158.
191. Shi X-B, Ma A-H, Xia L, Kung H-J, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62:1496-1502.
192. Yeh S, Miyamoto H, Chang C. Hydroxyflutamide may not always be a pure antiandrogen. Lancet 1997;349:852-853.
193. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998;95:7379-7384.
194. Fujimoto N, Yeh S, Kang H-Y, Inui S, Chang H-C, Mizokami A, Chang C. Cloning and characterization of androgen receptor coactivator ARA55 in human prostate. J Biol Chem 1999;274: 8316-8321.
195. Truica CI, Byers S, Gelmann EP. β-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709-4713.
196. Nishimura K, Ting H-J, Harada Y, Tokizane T, Nonomura N, Kang H-Y, Chang H-C, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C. Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator. Cancer Res 2003;63:4888-4894.
197. Miyamoto H, Rahman M, Takatera H, Kang H-Y, Yeh S, Chang H-C, Nishimura K, Fujimoto N, Chang C. A dominant-negative mutant androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002;277:4609-4617.
198. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator, ARA55, leads to an inhibition of androgen receptor transactivation and the agonist activity of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003;100:5124-5129.
199. Rahman MM, Miyamoto H, Takatera H, Yeh S, Altuwaijri S, Chang C. Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem 2003;278:19619-19626.
200. Lee Y-F, Lin W-J, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 2002;62: 6039-6044.
201. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 3β-Acetoxyandrost- 1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci USA 2003;100:4440-4444.
202. 5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci USA 1999;96: 11173-11177.
203. Desai A, Stadler WM, Vogelzang NJ. Nilutamide: Possible utility as a second-line hormonal agent. Urology 2001;58:1016-1020.
204. Oh WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002;60(Suppl 3A):87-93.
205. Chang C-Y, McDonnell DP. Evaluation of ligand-dependent changes in AR structure using peptide probes. Mol Endocrinol 2002;16:647-660.
206. Plonowski A, Schally AV, Nagy A, Sun BD, Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999;59:1947-1953.
207. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and androgen-independent human xenograft models. Cancer Res 1999; 59:4761-4764.
208. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of demamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001;86:5729-5736.
209. 2 in patients with hormone refractory prostate cancer. Clin Cancer Res 2002;8:2820-2827.
210. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma: A phase II trial of trastuzumab alone and with paclitaxel. Cancer 2002;94:980-986.
211. Lin H-K, Yeh S, Kang H-Y, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001;98:7200-7205.
212. Lin H-K, Wang L, Hu Y-C, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002;21:4037-4048.
213. Mitchell SH, Zhu W, Young CYF. Resveratrol inhibits expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999;59:5892-5895.
214. Zhang Y, Ni J, Messing EM, Chang E, Yang C-R, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 2002;99:7408-7413.
215. Dorai T, Cao Y-C, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 2001;47:293-303.
216. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20: 7597-7609.
217. Lieberman R. Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent development. Urology 2001;58(Suppl 2A):83-91.
218. Alberts SR, Blute ML. Chemoprevention for prostatic carcinoma: The role of flutamide in patinets with prostatic intraepithelial neoplasia. Urology 2001;57(Suppl 4A):188-190.
219. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
220. Andriole GL, Guess HA, Epstein JI, Wise H, Kadman D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J, for the PLESS Study Group. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52:195-202.